Rapid generation of pandemic influenza virus vaccine candidate strains using synthetic DNA

• Published in: Influenza and Other Respiratory Viruses
• Main Authors: Verity, Erin E., Camuglia, Sarina, Agius, Catherine T., Ong, Chi, Shaw, Robert, Barr, Ian, Middleton, Deborah, Rockman, Steven
• Format: Article in Journal/Newspaper
• Language: English
• Published: Wiley 2011
• Subjects: Whooper Swan
• Online Access: http://dx.doi.org/10.1111/j.1750-2659.2011.00273.x; https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1750-2659.2011.00273.x; https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1750-2659.2011.00273.x

Please cite this paper as: Verity et al. (2011) Rapid generation of pandemic influenza virus vaccine candidate strains using synthetic DNA. Influenza and Other Respiratory Viruses DOI:10.1111/j.1750‐2659.2011.00273.x. Background Vaccination is considered the most effective means of reducing influenza burden. The emergence of H5N1 and pandemic spread of novel H1N1/2009 viruses reinforces the need to have strategies in place to rapidly develop seed viruses for vaccine manufacture. Methods Candidate pandemic vaccine strains consisting of the circulating strain haemagglutinin (HA) and neuraminidase (NA) in an A/PR/8/34 backbone were generated using alternative synthetic DNA approaches, including site‐directed mutagenesis of DNA encoding related virus strains, and rapid generation of virus using synthetic DNA cloned into plasmid vectors. Results Firstly, synthetic A/Bar Headed Goose/Qinghai/1A/2005 (H5N1) virus was generated from an A/Vietnam/1194/2004 template using site‐directed mutagenesis. Secondly, A/Whooper Swan/Mongolia/244/2005 (H5N1) and A/California/04/09 (H1N1) viruses were generated using synthetic DNA encoding the viral HA and NA genes. Replication and antigenicity of the synthetic viruses were comparable to that of the corresponding non‐synthetic viruses. Conclusions In the event of an influenza pandemic, the use of these approaches may significantly reduce the time required to generate and distribute the vaccine seed virus and vaccine manufacture. These approaches also offer the advantage of not needing to handle wild‐type virus, potentially diminishing biocontainment requirements.